Coya Therapeutics, Inc. (COYA) Balance Sheet
COYA balance sheet, 2025
December 31, 2025 · U.S. dollars$50.0M assets = $6.9M liabilities + $43.0M equity
Both columns are drawn to the same scale: what COYA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
COYA financial health
Descriptive bands, not a rating. Fiscal 2025.
COYA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $8.7M2020 | $50.0M2025 | +41.7%/yr | |
| Total liabilities | $447,1212020 | $6.9M2025 | +73.0%/yr | |
| Shareholders’ equity | $8.3M2020 | $43.0M2025 | +39.0%/yr | |
| Cash & short-term investments | $8.7M2020 | $46.8M2025 | +40.0%/yr | |
| Total debt | $13.0M2022 | $723,8522023 | −94.4%/yr | |
| Net cash (debt) | −$7.0M2022 | $31.9M2023 | +$38.9M | |
| Working capital | $8.3M2020 | $44.1M2025 | +$35.8M | |
| Book value per share | $0.552021 | $2.572025 | +46.9%/yr | |
| Current ratio | 19.572020 | 8.502025 | −11.06 | |
| Shares outstanding | 6.6M2021 | 16.7M2025 | +26.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
COYA assets
COYA liabilities and equity
COYA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
COYA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | $8.7M |
| Cash & equivalents | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | $8.7M |
| Short-term investments | — | $38.30B | — | — | — | — |
| Receivables | $0 | $730,581 | $7.5M | $0 | $0 | $1,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $3.1M | $5.2M | $1.1M | $1.3M | $244,080 | $27,267 |
| Total current assets | $49.9M | $44.3M | $41.2M | $7.2M | $4.6M | $8.7M |
| Property, plant & equipment (net) | $11,227 | $38,588 | $65,949 | $93,310 | $120,671 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $1.1M | $87,181 | $0 |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M | $8.7M |
| Liabilities | ||||||
| Accounts payable | $1.1M | $1.6M | $1.2M | $1.8M | $857,567 | $447,121 |
| Short-term debt | — | — | $723,852 | — | — | — |
| Deferred revenue | $1.2M | $848,286 | $923,109 | — | — | — |
| Total current liabilities | $5.9M | $3.8M | $5.1M | $3.8M | $1.1M | $447,121 |
| Long-term debt | $0 | $0 | $0 | $13.0M | $0 | $0 |
| Other long-term liabilities | $1.1M | $945,447 | $574,685 | $0 | $857,567 | $447,121 |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M | $447,121 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $2,094 | $1,671 | $1,441 | $259 | $259 | $259 |
| Retained earnings (deficit) | −$62.0M | −$40.7M | −$25.9M | −$17.9M | −$5.6M | −$731,979 |
| Accumulated other comprehensive income | — | — | −$11,249 | — | — | — |
| Total shareholders' equity | $43.0M | $39.6M | $35.6M | −$8.4M | $3.6M | $8.3M |
| Key figures | ||||||
| Total debt | — | — | $723,852 | $13.0M | — | — |
| Net cash (debt) | — | — | $31.9M | −$7.0M | — | — |
| Working capital | $44.1M | $40.5M | $36.1M | $3.4M | $3.4M | $8.3M |
| Tangible book value | $43.0M | $39.6M | $35.6M | −$8.4M | $3.6M | $8.3M |
| Book value per share | $2.57 | $2.60 | $3.51 | −$0.84 | $0.55 | — |
| Shares outstanding | 16.7M | 15.2M | 10.2M | 9.9M | 6.6M | — |
| Current ratio | 8.50 | 11.59 | 8.15 | 1.88 | 3.99 | 19.57 |
| Quick ratio | 7.97 | 10.22 | 7.94 | 1.55 | 3.78 | 19.51 |
| Debt / equity | — | — | 0.02 | — | — | — |
| Equity / assets | 86.1% | 89.2% | 86.4% | −100.0% | 76.0% | 94.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $43.2M | $50.7M | $46.8M | $28.1M | $29.8M | $35.5M | $38.3M | $31.1M | $36.6M | $36.0M | $32.6M | $10.9M |
| Cash & equivalents | $43.2M | $50.7M | $46.8M | $28.1M | $29.8M | $35.5M | $38.3M | $31.1M | $36.6M | $36.0M | $32.6M | $10.9M |
| Short-term investments | — | — | — | — | — | — | $38.30B | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $730,581 | $730,581 | $0 | $0 | $0 | $7.5M | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $3.9M | $2.5M | $3.1M | $3.9M | $3.7M | $2.1M | $5.2M | $4.4M | $3.3M | $1.3M | $1.1M | $936,354 |
| Total current assets | $47.1M | $53.3M | $49.9M | $32.0M | $33.4M | $38.4M | $44.3M | $35.5M | $39.9M | $37.3M | $41.2M | $11.8M |
| Property, plant & equipment (net) | $5,614 | $8,420 | $11,227 | $18,068 | $24,908 | $31,748 | $38,588 | $45,429 | $52,269 | $59,109 | $65,949 | $72,790 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $244,727 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $47.3M | $53.3M | $50.0M | $32.0M | $33.5M | $38.4M | $44.3M | $35.6M | $39.9M | $37.4M | $41.3M | $11.9M |
| Liabilities | ||||||||||||
| Accounts payable | $1.1M | $948,192 | $1.1M | $1.1M | $931,344 | $1.7M | $1.6M | $336,722 | $1.9M | $1.6M | $1.2M | $633,951 |
| Short-term debt | — | — | — | — | — | — | — | — | — | $723,852 | $723,852 | — |
| Deferred revenue | $1.2M | $1.2M | $1.2M | $916,712 | $731,075 | $841,414 | $848,286 | $573,089 | $939,035 | $689,669 | $923,109 | — |
| Total current liabilities | $3.5M | $3.5M | $5.9M | $3.7M | $4.5M | $4.3M | $3.8M | $2.3M | $3.8M | $4.3M | $5.1M | $1.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $519,636 | $754,198 | $1.1M | $1.1M | $641,157 | $694,435 | $945,447 | $1.2M | $856,650 | $681,287 | $574,685 | $0 |
| Total liabilities | $4.0M | $4.3M | $6.9M | $4.8M | $5.1M | $5.0M | $4.8M | $3.5M | $4.7M | $5.0M | $5.6M | $1.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $2,346 | $2,346 | $2,094 | $1,675 | $1,673 | $1,673 | $1,671 | $1,523 | $1,523 | $1,462 | $1,441 | $996 |
| Retained earnings (deficit) | −$75.8M | −$69.2M | −$62.0M | −$56.3M | −$54.1M | −$48.0M | −$40.7M | −$37.8M | −$33.8M | −$30.9M | −$25.9M | −$27.1M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | — | — | −$149,250 | −$11,249 | $0 |
| Total shareholders' equity | $43.3M | $49.0M | $43.0M | $27.3M | $28.3M | $33.4M | $39.6M | $32.0M | $35.3M | $32.4M | $35.6M | $10.1M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | — | — | $723,852 | $723,852 | — |
| Net cash (debt) | — | — | — | — | — | — | — | — | — | $35.3M | $31.9M | — |
| Working capital | $43.5M | $49.7M | $44.1M | $28.4M | $28.9M | $34.0M | $40.5M | $33.2M | $36.1M | $33.0M | $36.1M | $10.0M |
| Tangible book value | $43.3M | $49.0M | $43.0M | $27.3M | $28.3M | $33.4M | $39.6M | $32.0M | $35.3M | $32.4M | $35.6M | $10.1M |
| Book value per share | $1.84 | $2.16 | $2.57 | $1.63 | $1.69 | $2.00 | $2.42 | $2.10 | $2.36 | $2.24 | $3.51 | $1.01 |
| Shares outstanding | 23.5M | 22.6M | 16.7M | 16.7M | 16.7M | 16.7M | 16.4M | 15.2M | 14.9M | 14.5M | 10.2M | 9.9M |
| Current ratio | 13.40 | 15.02 | 8.50 | 8.73 | 7.43 | 8.84 | 11.59 | 15.31 | 10.43 | 8.64 | 8.15 | 6.54 |
| Quick ratio | 12.29 | 14.30 | 7.97 | 7.67 | 6.61 | 8.35 | 10.22 | 13.39 | 9.56 | 8.33 | 7.94 | 6.03 |
| Debt / equity | — | — | — | — | — | — | — | — | — | 0.02 | 0.02 | — |
| Equity / assets | 91.5% | 91.9% | 86.1% | 85.1% | 84.6% | 86.9% | 89.2% | 90.0% | 88.3% | 86.6% | 86.4% | 84.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 16, 2026); data from EODHD.
COYA financial position
At the end of fiscal 2025 (December 31, 2025), Coya Therapeutics had total assets of $50.0 million (up 12.6% from a year earlier), total liabilities of $6.9 million and shareholders' equity of $43.0 million. Its current ratio was 8.50. In the latest quarter (ended June 30, 2026) total assets were $47.3 million and equity $43.3 million.
Related: COYA income statement, COYA cash flow statement, COYA key metrics. See the COYA stock overview for the latest quote and news.
COYA balance sheet FAQ
What are Coya Therapeutics's total assets?
Coya Therapeutics reported total assets of $50.0 million at the end of fiscal 2025 (December 31, 2025), compared with $44.3 million a year earlier.
How much cash does Coya Therapeutics have?
Coya Therapeutics held $46.8 million in cash and short-term investments at the end of fiscal 2025.
What is Coya Therapeutics's book value?
Coya Therapeutics's shareholders' equity (book value) was $43.0 million at the end of fiscal 2025, or $2.57 per share.
What is Coya Therapeutics's current ratio?
Coya Therapeutics had current assets of $49.9 million and current liabilities of $5.9 million, a current ratio of 8.50 (it can cover its short-term obligations).